With the approval of new drugs by Eisai and Biogen, genetic testing for Alzheimer’s is on the rise.
This article from Reuters cites a 125% increase in ApoE genetic testing in a four-month period around the approval of the Biogen drug in January. This was determined after review of medical records from nearly 8 million adults across 28 major US hospitals, so it did not account for any increase in DTC genetic testing. Since anti-selection is always a concern, this trend is worth noting.
Tags: Alzheimers, Genetic Testing, Life Insurance, Underwriting